This clinical trial is focused on studying a condition called macular edema, which is a swelling in the central part of the retina, known as the macula. This swelling is caused by a blocked vein in the retina, a condition referred to as retinal vein occlusion. The study is investigating the effectiveness and safety of a medication called aflibercept, which is given as an injection into the eye. Aflibercept is a protein-based treatment that helps reduce swelling and improve vision.
The purpose of the study is to compare two different doses of aflibercept. One group of participants will receive 8 mg of aflibercept every 8 weeks, while another group will receive 2 mg every 4 weeks. The study aims to determine if the higher dose given less frequently is as effective as the lower dose given more frequently. Participants will receive injections over a period of time, and their vision will be monitored to see how it changes with the treatment.
Throughout the study, participants will have their vision tested using a method called the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score, which measures how well they can see letters on a chart. The study will also track the number of injections participants receive and any side effects they may experience. The goal is to find the best treatment option for improving vision in people with macular edema due to retinal vein occlusion.
Austria 
Bulgaria 
Czechia 
Estonia 
France 
Germany 
Hungary 
Italy 
Latvia 
Lithuania 
Poland 
Portugal 
Slovakia 
Spain